THE ORIGINS OF INTERPRET
Magnetic Resonance Spectroscopy (MRS) of cancers in the human body, which has been possible for 30 years (1) , provides a unique and entirely non-invasive method for detecting and quantifying metabolites within tumours. It can nowadays be performed on standard clinical MRI instruments; obtaining a matrix of MR spectra from a suspicious cerebral mass adds about 20 minutes to a routine diagnostic evaluation of a patient. However, despite many years of successful research, MRS is rarely used as a routine clinical method. Likely issues that have inhibited its use include (i) the unfamiliarity of the spectra it produces, which are unlike any data normally used in medical diagnosis; (ii) a perceived requirement for an understanding of biochemistry and metabolism on the part of the end-user; and (iii) the need for timeconsuming and expert data manipulation, especially if quantitative metabolite concentrations are required.
During the early 1990s Sian Howells and colleagues demonstrated that subjective expert interpretation of MR spectra was not always necessary, since computer-based pattern recognition methods (sometimes termed "chemometrics") could classify spectra from animal tumour biopsies (2) and from animal tumours scanned non-invasively in vivo by 31 
P MRS (3).
Several studies over the next few years (4, 5) demonstrated that statistical methods could be used to classify 1 H MR spectra of human brain tumours, indicating both the type of brain tumour (glioma, meningioma etc.) and in some cases its grade of malignancy. A highly malignant glioblastoma multiforme, for instance, has a completely different spectrum from a low-grade glioma ( Figure 1 ).
Although the statistical methods used largely eliminated issue (ii) -the need for understanding the underlying biochemistry -, expert intervention was still required to assign peaks and to quantify the corresponding metabolites, before data could be entered into the classification algorithm. Consequently, these early statistical methods were not widely adopted for routine clinical use.
In contrast, the chemometric classification methods that had originally been developed by Howells (3, 6) had used "raw" spectra, with no quantification or even assignment of the peaks.
If such an approach could be applied to in vivo 1 H spectra of human tumours, there would be no need for any understanding of the underlying biochemistry or for expert data manipulation, addressing issues (i) and (iii) above. The way would then be open for the development of a completely automated method for spectral classification that could be used by radiologists or other medical practitioners who had no specialist knowledge of MRS. To achieve this aim, it would be necessary to gather a sufficiently large dataset of spectra from tumours with known diagnoses, and then to design an algorithm that would compare a spectrum from a patient undergoing diagnosis with the standard spectra in the database.
With this aim in mind, the initial grant application for what became the INTERPRET project was developed in the late 1990s by Rosemary Tate and John Griffiths, who were then at St
George's Hospital Medical School, London, responding to a call from the European Union Framework 5. However, several issues had to be addressed before the application could be completed (7).
Design of the INTERPRET collaboration
First, it was clear that no single hospital would see sufficient patients to be able to create a database of the size required for automated spectral analysis, so a collaborative project would be required. Second, there was at that time no consensus as to the best algorithm for classifying the spectra, or indeed the most useful features of the spectra that could be used by the algorithm. Thus the collaboration would have to include data analysis experts. It would also be necessary to provide data early in the project for the data analysts to start their work, which was accomplished by creating a preliminary database of retrospective cases, dating as far back as 1994. Retrospective spectra were accepted if they had been obtained using protocols compatible with those used to obtain the prospective spectra, and if their clinical data passed the same validation protocols as prospective cases.
A third issue was the way in which the results would be made available to the user. Bearing in mind the large variety of cancer types, some of them very rare, it was unlikely that a prototype system could function as a "black box" that gave a simple diagnosis, even within one class of tumors. Building on preliminary work at Sussex University (8) it was considered that the best approach was to implement a decision support system (DSS) that would display the unknown case in a feature-space that allowed the user to see how closely it corresponded to the spectra of cases with known diagnoses. Since it was expected that most users would be radiologists, it would be desirable to store images alongside their spectra, together with a limited amount of clinical data, so that the user would be able to call up the spectra, images and clinical details of individual cases. All this information from each standard case would need to be uploaded into the developing database over the web and then be subject to quality control and curating.
Experts in all these matters were therefore recruited to the collaboration.
Brain tumours were the obvious exemplar for several reasons. Lesions in the brain give better spectra than those from other parts of the body, because (i) the normal brain lacks the lipid deposits present in most normal tissues (although scalp lipids can be a problem for some peripheral brain tumours), which give confounding peaks in tumour spectra; (ii) the brain is not subject to significant respiratory motion; (iii) it was already known that brain tumours could be classified from their 1 H spectra (4, 5) ; (iv) most brain tumours are currently diagnosed by a histopathologist, using a specimen obtained by stereotactic needle biopsy, which is a very unpleasant experience for the patient and incurs morbidity and even mortality (9) (10) (11) , so a method that could improve the certainty of radiological diagnosis and reduce the need for biopsy would be welcome (12) ; (v) several European groups were already working on brain tumour MRS, which facilitated the recruitment of collaborators.
Several issues had to be addressed concerning histological verification of the diagnoses. The majority of cases would be tumours that had been diagnosed and graded by histopathology, either from needle biopsies or surgical specimens. These diagnoses were assigned by a group of pathologists who checked each other's diagnoses for consistency. Cases diagnosed without histological examination (e.g. lymphomas, and "pseudotumoural" neurological lesions such as multiple sclerosis lesions or abscesses which can occasionally be mistaken for tumours) were checked by the Clinical Data Validation Committee (CDVC), consisting of practising neurosurgeons, neuroradiologists and cancer clinicians within the collaboration, which also reviewed and validated the clinical, MRI and surgery data associated with all the spectra.
Another problem was MR system heterogeneity. The collaborating institutions used 1.5T MRI instruments from the three major manufacturers (General Electric, Philips and Siemens) but these instruments and their associated software were of different models and generations.
Furthermore, both the instruments and the MRS methods would be constantly updated or even replaced during the period of accrual of spectra. The classification method would therefore have to be able to deal with differences in the spectra due to the different instruments, pulse sequences and other technical matters and to focus only on the type and grade of the tumours. In any case, a classification system that could not cope with spectra obtained on different instruments and with different pulse sequences would be unlikely to be of much practical value.
The EU call required that the collaboration should include commercial partners to ensure that the diagnostic tool developed by INTERPRET would be commercially marketed, so a software company (PRAXIM) and an instrument company (Siemens) were invited to join in. (Table 1) .
MR methods
In 2000, 1.5T was state of the art in clinical magnets and the participating centres used the following 1.5T machines: GE Signa, Signa Advantage, and LX CV/i 1.5T, Philips NT and ACS NT 1.5T and Siemens Vision 1.5T. Consensus acquisition parameters for Single Voxel spectroscopy are summarised in Table 2 . Before the MRS acquisition, a basic set of MR images was acquired to aid voxel placement, ensuring that it was entirely located within the lesion and avoiding contamination from normal adjacent brain tissue or oedema. When contrast was administered, MRS was performed after contrast. Two centres also performed multivoxel MRS imaging (MRSI), one using the PRESS long TE protocol and the other with the STEAM short TE protocol (http://gabrmn.uab.es/interpret/mrs_data/mrs_data.html).
MRS processing pipeline
Consensus acquisition protocols were developed to minimise differences in the data format and the post-processing algorithms and methodologies were standardised (13, 14) . In 2000, the DICOM standard for spectroscopy was still under development, and retrospective data came with a rich variety of spectral widths and numbers of data points (Table 2) . Therefore, an automated processing pipeline, the data manipulation software (DMS), was developed for converting spectra into an "INTERPRET Canonical Format", a 512-point spectrum covering the The canonical spectra had three different uses: (i) classifier development, (ii) display of the spectrum for quality control, (iii) allowing radiologists to input spectra into the DSS, without the need of cumbersome manual processing.
Databases
Three databases were developed during the project. The INTERPRET preliminary database which was used for the initial pattern recognition experiments in the early stages of the project. The INTERPRET comprehensive database (iDB) which contained all the cases accrued during the project; and the validated INTERPRET database (viDB) (15) which contained the subset of iDB cases that fulfilled all quality control criteria (Table 4) .
Quality control of MRS data
The quality assessment system ensured traceability of records and quality control (QC) records for both MRS and clinical data (16). Each instrument's performance was checked bimonthly and, more rigorously, annually by measurements on a specially designed phantom and by spectra obtained from five healthy volunteers per centre. QC of MR spectra uploaded to the database was performed automatically on two indices calculated by the DMS: the signal-tonoise ratio of the processed spectrum and the linewidth of the water peak in the unsuppressed water file (Table 4) . A final manual check by a committee of expert spectroscopists looked for other artefacts such as large baseline distortions, insufficient removal of the water peak or large phasing errors. All this QC information is stored in the iDB as metadata.
Quality control of clinical data
The CDVC (http://gabrmn.uab.es/interpret/clinical_data/clinical_data.html) verified each case and tagged those suitable for classifier development. The main criteria were a consensus diagnosis and appropriate clinical information (i.e. age, sex, tumour location).
Histopathological assessment was performed on a sample obtained from the surgical specimen or, in some cases, from a pre-operative stereotactic biopsy. Two expert pathologists had to agree the diagnosis (15, 17) . Additionally, CDVC meetings checked that voxel positioning had been performed according to the protocols and that the diagnostic biopsy had been taken from the place where the voxel had been positioned.
Classification of MR spectra
The project eventually accrued 775 cases with MR data (mostly single voxel, partly multi voxel). The database inevitably contained more cases from common cancers and rarer types were represented by too few cases to form an adequate training set. It was therefore necessary to aggregate together certain cancer types in order to have large enough groups for classifier development.
A key issue, as previously mentioned, was to devise software classifiers that would categorise the spectra purely according to the metabolic profiles of the different classes, and would not be influenced by issues such as the scanner brand, the pulse sequence or the echo time. A preliminary study (18) developed classifiers using spectra obtained with different instruments, using STEAM or PRESS sequences, and with TE values that varied from 20 to 32 ms. None of those factors affected classification performance, provided that all the spectra had been processed in the same way and interpolated to the same number of points and sweep width.
The definitive INTERPRET classifier, a short TE classifier for most common brain tumour types, was developed using features selected by correlation analysis (18) . The classifier was trained to distinguish groups of tumour classes: (i) low-grade glial tumours (LGG) (comprising A2, OA and OD); (ii) aggressive tumours (AGG), (comprising GB and ME); and (iii) low-grade meningiomas (MN) which included meningiomas of WHO grades I and II. The number of features was restricted according to the size of the training set (generally n/3, where n is the number in the smallest group) to avoid overfitting (19, 20) . The "LGG vs. AG vs. MN" classifier gave excellent results with the independent test set (89% accuracy) and the short TE classifier was chosen over the long TE one for its slightly better performance. Development of a "GL vs. ME"
classifier was also attempted; it showed reasonable results (70-80% correct classifications)
when data from a single centre were used, but when training data from one centre were tested with data from the other centres (18) accuracy dropped to about 62% (short TE) and
48.7% (long TE).
These INTERPRET classifiers, developed at SGUL by Rosemary Tate, used a very simple technique, linear discriminant analysis, run on commercial programs (SAS, SPSS). In another study, Christophe Ladroue and the SGUL group explored the potential of non-linear methods (21) to automatically decompose a given spectrum into "independent components", corresponding to the different metabolites. The group of Sabine van Huffel from the University of Leuven, also compared the performance of linear and non-linear classifiers in two different studies, one devoted to short TE (22) and the other to long TE (23) and they found that linear and non linear methods performed similarly.
There were also attempts to build classifiers using the multivoxel data. A first approach was the use of the information contained in the variously acquired MRI images (T1, T2, Proton
Density and Gadolinium enhanced T1). Unsupervised classifiers were constructed in order to segment an image and identify the possible tumorous area in an objective way. A supervised classifier (linear discriminant analysis) allowed discrimination between healthy and tumor regions. In addition, it allowed discrimination between oligodendrogliomas and astrocytomas for a limited set of patients (24) . A next step was the combined use of MRI and MRSI data.
After post-processing, several MRSI peaks were quantified and the MRSI images were aligned with the MRI image data. The MRI intensities of each MRI image modality corresponding to each voxel were then quantified. Using an unsupervised classifier it was possible to segment the voxels in the volume of interest, to identify the deviating and possibly tumorous area and to detect possible heterogeneity (25) . Supervised classifiers were also built, based upon these data (26) . This system was capable of segmenting and identifying the volume of interest into voxels belonging to healthy tissue, cerebrospinal fluid, WHO grade II, II and IV glial tumours, unknown areas and voxels on which no decision could be made. The voxels could be coloured according to these classes and an associated probability of each class was provided. This resulted in a prototypical Decision Support System for multivoxel data (27) ( Figure 2 ).
The Decision Support System (DSS)
The DSS was developed by the Human-Computer Interaction team at the University of Sussex (8) . Key users (radiologists and spectroscopists, both experts and beginners in MRS) , helped to set the functional requirements of the system, and later to evaluate versions of the system containing preliminary datasets and classifiers (28) . Usability aspects evaluated included whether a 2D or a 3D display of cases was more useful, and how the system was used by different user types, with a camera recording the user's actions for further analysis. The final DSS prototype (28) scatterplot. Users can enter a spectrum from an undiagnosed case, which is then automatically positioned in the scatterplot, and they can compare their unknown spectrum to those of the cases in the database using the two right-hand spectral visualisation panels. Individual spectra can also be compared to averaged plots of the different tumour classes, showing their mean spectra and standard deviations. The user can also create overviews of cases, as 2D scatterplots of ppm heights or ppm height ratios.
INTERPRET AFTER INTERPRET
At the end of its 3-year funding period, in December 2002, the INTERPRET project had successfully developed a prototype DSS and its associated database of spectra, and had performed initial tests which verified that use of the prototype DSS by radiologists could significantly improve their diagnosis and grading of tumour spectra. Work on many aspects of INTERPRET has continued, however.
From the INTERPRET DSS prototype to the industrial INTERPRET DSS
To turn the prototype DSS into a commercially marketable system, PRAXIM, one of the participating industrial partners, developed the "Industrial INTERPRET DSS". In 2003, PRAXIM passed its rights to SCITO, a related company, which continued that work.
In the first step towards CE accreditation, the UAB team verified the traceability of all the cases in the database, giving a final list of 304 cases. SCITO then re-engineered the system to make it automated and robust. The outcome was a client-server application called RADIONET, which was intended to provide a unified solution for the radiological examination process, with the spectroscopy as one of the modules of the RADIONET system (29), it was able to benefit from the lessons learned during INTERPRET, particularly with respect to the acquisition protocols, quality control strategies, database, pattern recognition methods and DSS.
Database preservation
The final version of the INTERPRET iDB contains MRS data (SV or MV spectra) for 775 patients (Table 1) . Since paraffin biopsy sections could not be obtained from all retrospective cases, a consensus histopathological diagnosis is available for 477 cases. The number of cases with at least one good quality SV short echo spectrum, acquired from the solid part of the mass in the region where the biopsy or tumor resection took place is 282. These cases, together with data from 22 normal volunteers, form the viDB (15) , which continues to be the project's publicly available database (http://gabrmn.uab.es/interpret/int_Disc_FrozenDB.shtml). The viDB can be accessed by two modalities. Anyone requesting access for scientific or medical purposes can be granted "view permission", i.e. being able to look at the data but not being able to download either the processed or the unprocessed spectra; it has resulted in about 50
requests. The second modality provides permission to download the raw data. The download facility is available upon request to the coordinator, who then has to obtain the necessary permission from the original data-contributing partners of INTERPRET. This type of access has been granted to four research groups and two consortia (eTumour and HealthAgents (30)). The data sharing schema has been very successful, allowing numerous pattern recognition studies to be performed on the existing data (31-51), although it should be noted that only those accesses that have involved a scientific collaboration have led to publications.
The complete iDB has been a relatively unexploited resource, particularly those cases with different degrees of validation and completeness. Both INTERPRET databases are administered and maintained by the UAB team.
Using the DMS with the new MRS data formats
Further developments in the DMS have taken place during the post-INTERPRET period. The DMS pipeline has also undergone some minor adjustments: Instead of shell scripts it now uses the C language, and line broadening is now set to 1Hz instead of the 0.8 Hz used in the original study. At UAB, Guillem Mercadal developed the jDMS (52), a java based MRS format conversion software, which translates any spectrum processed with jMRUI into the 512-point INTERPRET canonical format. Using jDMS, manually processed spectra can be automatically converted to the canonical format (52) . jDMS eliminated the need for constantly updating the DMS MRS format conversion routines to cope with the numerous MRS formats and updates that have appeared in the 12 years since the original software was developed, keeping the DSS alive and usable. It also permits the use of jMRUI for manual correction of the phase of those spectra in which the Klose algorithm does not work perfectly. The jDMS was, de facto, adopted as the general solution by the eTumour (29) and HealthAgents (53) consortia, both to provide database display of processed spectra in any format after 2002, for quality control purposes, and also to obtain data matrices for classifier development using these multicenter datasets (31, (33) (34) (35) (36) 38) , and for the CURIAM DSS (54), which derived from these projects. The jDMS also greatly facilitated scientific collaborations with artificial intelligence research groups who could obtain a consistent, clean data matrix without having to learn how to phase a spectrum or process MRS data . Currently, the DMS pipeline is being integrated into the MRUI software as a plug-in (http://www.transact-itn.eu/). The idea is to automate the data processing of any SV or MV spectral format, ready for exporting the processed files into pattern recognition algorithms or into the INTERPRET DSS.
Pattern recognition: does the particular method matter?
Sharing the SV INTERPRET data resulted in numerous published studies (31-44) which mainly developed classifiers or feature extraction methods. The INTERPRET data was used either as the training set for developing new classifiers or as a test set for the classifiers that had been developed. Both approaches were used in a study performed by eTumour (33) , in which 253 pairwise classifiers for GB, MN, ME, and LGG were obtained for 211 short TE spectra from INTERPRET (the training set) and 97 spectra from eight different centres of the eTumour consortium (the test set).
What were the lessons learned from the pattern-recognition studies?
Single voxel
1. Classifiers developed in this way are robust, and perform well on independent data from several centres and manufacturers, acquired at different times by different operators.
2. Most studies addressed relatively easy problems that gave results of around 90% (whether it in terms of accuracy, AUC, or any other measure of efficacy) (33) , no matter what feature extraction or classification method were employed. The basic paradigm continued to be the "most common tumour types" problem, first attempted for "LGG vs. AGG vs. MN" in the original INTERPRET study (55 and AB were tested. In the main INTERPRET-eTumour paper (33), the seven bilateral combinations were between the GB, ME, MN classes and the AGG superclass. In the latest study using the INTERPRET data, published in 2013 (49), the classes were: "LGG vs. ME", "MN vs.
LGG", "LGG vs. GL", "MN vs. GL", "MN vs. NO (normal tissue)" and "GB vs. ME".
3. Difficult problems have more rarely been attempted, the paradigm being "GB vs. ME".
Despite having very different (and in the case of ME, very heterogeneous) origins, these two groups of tumours have remarkably similar spectra, so GB and ME were originally joined into a single group for analysis of multiclass (i.e. more than two classes) problems (22, 23) . Discrimination of GB from ME is a case in which the importance of using an independent test set can be observed. Studies that attempted this bilateral discrimination without using a test set, for example (44, 48, 50) , have claimed results in the 90% range. In contrast, in most studies that used an independent test set to evaluate the robustness of the their classifiers performance was no better than random (23, 33, 49) . A successful classification was achieved in one study (51) were first recognized in a study (31) that used an already curated dataset of INTERPRET cases. The same problem was found in the INTERPRET-eTumour study (33) . Another study (41) used Sammon's mapping for visualization of cases, coupled to generative topographic mapping to automatically identify outliers. They were categorized into artifact-related (outliers caused by artifacts) and class-related (spectra that are outliers with respect to their class).
5. Short and long TE spectra can be concatenated together and then provide help in some bilateral discriminations, e.g. the "GB vs. ME" problem (51), or to distinguish meningiomas from other tumour types (31).
6. 3T data and 1.5T data, processed with the DMS and converted to the INTERPRET canonical format, can be compatible in terms of classification (35) . This study trained a classifier with
short TE INTERPRET spectra and tested it with sets of short TE eTumour spectra obtained at 1.5T and 3T. The classification problem was "AGG vs.
LGG", either using peak heights or integrated peak areas, and simple classifiers (LDA, KNN and ANN). The results on the test set were similar for the 1.5T and the 3T sets, despite the training set consisting mainly of 1.5T spectra.
In a further development of the INTERPRET approach, the Barcelona group at UAB developed SpectraClassifier (56), a user-friendly program that enables biochemists and other users with no expertise in pattern recognition to make their own MRS classifiers for clinical data and preclinical models. It includes simple tools for feature extraction (PCA), selection (greedy stepwise (57)) and classification (fisher LDA). The system has been successfully used in classification of MRSI data of preclinical models (58) and human tumours (52) .
Multivoxel
The studies performed on MV data after INTERPRET follow the path set by Arjan Simonetti, in which the original dataset accrued and analysed during the project was later used in different Tumour heterogeneity (66) , was tackled in different ways: either by assigning voxels of "unknown" pathology to those voxels that did not reach a certain threshold of Mahalanobis distance to the centroid of the class (26) or by a two-step process in which tumour typing is followed by a segmentation in which the model of "mixed tissue" is introduced (59) .
Decision support systems
While the MV interface was not further developed, the SV INTERPRET DSS developed by UAB has evolved into the current 3.1 (52), keeping the look and feel of the original. It currently has classifiers for three different problems: "most common tumor types", "tumour vs.
pseudotumoural" disease (67), and "GB vs. ME" (51) . It keeps the "make your own overview" feature, allowing users to make peak height or ratio plots. It also offers the possibility of using short, long or short and long TE spectra of the same case. In fact, the "GB vs. ME" classifier requires the input of short and long TE spectra when entering a new case for analysis (51) . The multiplicity of classifiers now means that the user must have a clear idea of the question to be answered and whether to attempt the analysis with short TE, long TE or combined TE spectra. A lesson learned from (68) was that, radiologists from public health system centres would not have the time to embark on formal evaluations of a DSS. Therefore when it was necessary to check whether a new version of the system, offering the choice of an added long TE classifier would give results consistent with those from the prospective study, 6 radiologists with no particular knowledge of spectroscopy and 3 expert MR spectroscopists were left free to use the system to categorise these 40 cases. In most classes and superclasses of brain tumours the AUC were not significantly different from the first study (68) (71, 72) . This study demonstrated that radiologists with no expertise in spectroscopy can use the system, by adhering to basic guidelines. The ability to choose an echo time other than short TE did not affect results, which does not seem to agree with previous literature on classifiers (31, 69) , however the exact use of the system was not recorded. whereas with MRS and the DSS it was 89% and 84% respectively. All 14 biopsied GB patients were diagnosed as GB using a single neuroradiologist and as high-grade by the DSS. On the basis of their 100% success rate with these biopsied patients the authors suggested that the DSS could be used as a confirmatory test in the quite large group of patients for whom brain biopsy would be contraindicated (about 25% in the Barcelona study (68) , such as those with poor functional status or with an unfavourable lesion location.
Taking together, these three evaluations show that the system behaves robustly when used in different ways by different classes of users. It can be used either as for visualising the effects of classifiers or for decision-suppport, and importantly, to analyse spectra from pathologies for which there is not a specific classifier. In the latter case there will be differences in performance depending on the experience of the person using it and the protocol, which can be critical for certain tumour types, such in as astrocytomas of WHO grade III.
The DSS has been distributed to about 200 users and it is currently in use at Uppsala University 
ACHIEVEMENTS OF INTERPRET AND POSSIBLE FUTURE DEVELOPMENTS
The INTERPRET collaboration set out to develop a non-invasive method for diagnosing and grading brain tumours using 1 H MRS, one that would eventually substitute the subjective analysis of a biopsy in cases where such biopsy is not available or advisable, and would require no understanding of MRS or biochemistry on the part of the user. To do that it accrued several hundred quality-controlled spectra, along with their associated MRI images, histopathology and clinical details; eventually the uploading and quality control procedures were automated.
INTERPRET also developed and tested numerous mathematical classifiers and created a decision support system -the DSS -for presenting the data to the user; finally, the overall prototype system was tested several times. How well did INTERPRET succeed in its aims?
Successes
A major technical problem that was solved by the INTERPRET consortium was development of a data input procedure that could cope with the proliferation of incompatible and constantly changing MRS data formats used by the three major manufacturers. This, however, required frequent modification of the DMS data input section, which could not be continued once the project's funding ceased. The development of the jDMS obviated the need for this updating, but introduced weaknesses that will be discussed in the next section.
Additional early successes for INTERPRET were the production of classifier algorithms that worked with raw spectra rather than the metabolite concentrations or integrated peak areas required by previous classification programs, and the demonstration that a useful database could be created by combining spectra acquired on instruments from different manufacturers, using fundamentally different acquisition protocols and numerous generations of software.
The software classifiers could be "taught" to ignore all these irrelevant issues and focus only on the differences between the tumour classes. It was even possible to classify 3T spectra using a database composed of 1.5T spectra (35) . These achievements are of value in their own right, as they suggest that other pattern recognition programmes of this type could be created.
Several clinical studies have tested the practical usefulness of the INTERPRET prototype. In view of the limited numbers of tumour classes that were adequately represented in its database, it was not expected that the prototype would be able to make definitive diagnoses.
Despite those initial misgivings, it has performed successfully in several prospective clinical tests, and it is clear that for certain classes of tumour, notably low-grade glial tumours, it significantly improves the diagnostic ability of experienced neuroradiologists.
The INTERPRET prototype is still in regular use more than a decade after the project ended.
Its database has provided a resource for many studies, particularly those that developed new classifiers, and it is even used by some clinicians to assist diagnosis. It also has a role in teaching. Furthermore, two subsequent EU collaborative projects, eTumour and HealthAgents were built on the foundations laid by INTERPRET.
Weaknesses
There were a number of obvious weaknesses of the INTERPRET project outcome. Because of the limited size of its database it was necessary to aggregate some tumour types into unfamiliar groupings (e.g. "AGG" or "
LGG"), while many rarer tumour types were not represented at all. This limits the routine use of the DSS for clinical diagnosis. The same problem meant that the DSS was not configured to offer a proposed diagnosis with a percentage probability, a feature that some users find desirable, or even essential.
Another structural weakness (overcome by brute force during the project itself) was the need for constant updating of the format conversion routines due to changes in the various manufacturers' data formats. Now that regular updating can no longer be supported the jDMS input program has permitted the on-going use of the INTERPRET system by many researchers and clinicians. However, before uploading a spectrum for classification it is now necessary to process it both with jMRUI and jDMS, so the original aim of developing a system that required the user to have no knowledge of MRS has been compromised.
A more fundamental problem is that the classifiers developed so far are not able to make clinically important distinctions, e.g. beween lymphomas from other grade IV brain tumours, or between glial subclasses or grades.
This could be partly due to the fact that conventional histopathological grading of brain tumours can be difficult (and subjective), particularly for distinguishing intermediate grades (75) (76) (77) (78) (79, 80 ).
An objection to the whole idea of developing a non-invasive method for brain tumour diagnosis is that "They are all going to be operated on anyway so why not just biopsy them?".
As has been mentioned, however, a significant number of patients with suspicious intracerebral massess are not, or should not be biopsied. In addition, efforts are being made to develop more anticancer drugs that will cross the blood-brain barrier. If non-surgical treatment of brain tumours by chemotherapy (and possibly also radiotherapy) becomes possible then a non-invasive diagnostic test would have great value.
Can the INTERPRET concept be further developed?
Even though MRS has been around as long as MRI, and even though it can be performed on most MRI instruments with minimal upgrading, it has never entered routine clinical use. The original impulse to develop INTERPRET came from a desire to find a "killer app" for MRS -that is an application that would be so compelling that it would cause users to purchase the necessary equipment and software. From a health economics perspective, bringing MRS into routine practice requires that the costs associated with the additional imaging and radiologist reporting time, are balanced against a significant increase in diagnostic performance and the resulting costs of the downstream investigations and treatments. Although successful in many ways, INTERPRET did not pass the "killer app" threshold. What would a future version need in order to bring MRS into routine use for brain tumour diagnosis?
1. Clinical needs:
1.1. Diagnosis prediction. Ideally, the system should diagnose and grade all the cancer types and grades that routinely present at a brain cancer centre although there is no certainty, of course, that all tumour types and grades will have MRS-detectable differential features. The system should also be able to advise a user about which tumour types can not be distinguished with MRS at each particular field or acquisition conditionsHowever, to make routine diagnoses , many more classifiers would also have to be developed including:
Grade IV tumours (LY vs. PN vs. GB vs. ME). numbers (~20) of cases of all the major cancer types and grades (although there will always be some cancers so rare that they cannot be scanned in adequate numbers). This database should also include other types of patients, i.e. children.
Given the constant technical improvement in spectroscopic techniques (81, 87, 88) , the database should be an open-ended project.
1.1.3. The system should be particularly optimized to give diagnoses for brain masses in patients who cannot (e.g. because they are too old, too young, too sick etc.) or
should not (because their masses will not be surgically removed -e.g.
lymphomas, abscesses etc.) be biopsied. (93)) and the SIVIC software framework (94) are steps in the right direction.
Planning a new DSS and larger database leads to a third problem: who would own and maintain them? One solution would be to develop a commercial DSS that could be sold to users or to MRI instrument manufacturers. The ownership of the database necessary for the use of that DSS (and also for the use of the INTERPRET prototype DSS) is a more difficult question. The current iDB and viDB consist of de-identified spectra obtained from patients in many different countries. All these patients gave informed consent, but numerous national legal frameworks were involved. These databases are owned by the original INTERPRET partners who allow them to be used by the INTERPRET DSS. If a larger database is to be developed it would probably be simplest if it is also owned and maintained by a noncommercial entity, as it would be challenging (and probably expensive) to develop a legal framework that allowed its commercial ownership. One possible solution would be to integrate it in a large data infrastructure such as Elixir, which is currently under construction (http://www.elixir-europe.org/about/rationale). An alternative approach to these technological and medico-legal challenges, would be not to have a centralised database but rather a cloud database of cases, whereby each contributing centre owns and manages its own local database, sharing only de-identified spectral features that are relevant for classification.
Patient consent would then only be required if, in the course of a prospective evaluation of the DSS, patient management would be affected by the system recommendations. This alternative approach poses the technological challenge of redesigning the classification algorithms, so that they can learn and classify based on distributed datasets, which is already an active area of research (95, 96) . This concept, using agents (30) had already been explored during the EU project HealthAgents (37, (97) (98) (99) but, unfortunately, with no practical continuity or commercial exploitation after the funding period ended.
All the studies performed so far have been designed to demonstrate that use of MRS data by the prototype DSS improves diagnostic power. When we are developing a DSS for practical clinical use we should consider developing classifiers that use both MRS data and clinical or MRI data. Simple parameters such as the patient's age and sex are already available in the database and could significantly refine certain diagnoses. Another source of information that could be exploited in a future system would be the MRI images (or indeed any other images) of the tumour. Texture analysis software could produce quantitative parameters that could be used by a classifier (100, 101) . All these data would be easily accessible to a radiologist.
One final speculation: it has always been tacitly assumed that the aim of INTERPRET and its subsequent developments was to reproduce the diagnosis made by a histopathologist. In reality, it is not impossible that MRS-based classification of cancers might improve on histopathology. MRS detects changes in the spectral pattern caused by small-molecule metabolites, lipids and even macromolecules in the living tumour, all of which contain a different type of information from that available on the classical microscope slides used for histopathology, or even from the genomic data that are nowadays coming into use for tumour classification (82, (102) (103) (104) (105) .
Perhaps, for instance, MRS-based classifiers could be devised that will provide a more accurate prognosis for some brain tumour sub-types (79, 106, 107) , or define sub-categories that would help to personalize the treatment of patients. Studies of that type will require another level of information gathering. Long-term data on disease progression and treatment response will have to be collected for the patients whose spectra are in the database and then classifiers constructed that will act as prognostic (i.e. course of disease) and predictive (i.e. response to treatment) biomarkers. Finally, it will be necessary to make prospective predictions by using those classifiers on a new cohort of patients and then to wait several years and see whether the predictions were accurate. The big challenge here would be to develop strategies that may work, at least partially, in a non-supervised or semi-supervised way (46) . MRS is already more than 30 years old: let us hope that its future is long enough for these possibilities to be realized.
8564 words Normalisation of spectrum to Euclidian norm of peak heights Table 4 . Consensus QC of all spectral data.
